APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurokinin Receptor Antagonists for Vasomotor Symptoms

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Growth and Trends Forecast to 2032

28 December 202578 pages

Choose your research edition.

Industry ResearchNeurokinin Receptor Antagonists for Vasomotor Symptoms Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Growth and Trends Forecast to 203278 pages · $3,450 USDMarket StructureGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Neurokinin Receptor Antagonists for Vasomotor Symptoms market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neurokinin Receptor Antagonists for Vasomotor Symptoms include Astellas Pharma and Bayer among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Neurokinin Receptor Antagonists for Vasomotor Symptoms market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Neurokinin Receptor Antagonists for Vasomotor Symptoms market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neurokinin Receptor Antagonists for Vasomotor Symptoms market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neurokinin Receptor Antagonists for Vasomotor Symptoms.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Neurokinin Receptor Antagonists for Vasomotor Symptoms market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Company

Astellas Pharma

Bayer

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Type

Fezolinetant

Elinzanetant

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Application

Hospital and Clinic

Pharmacy

Other

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurokinin Receptor Antagonists for Vasomotor Symptoms market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurokinin Receptor Antagonists for Vasomotor Symptoms and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurokinin Receptor Antagonists for Vasomotor Symptoms.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neurokinin Receptor Antagonists for Vasomotor Symptoms manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Neurokinin Receptor Antagonists for Vasomotor Symptoms in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Fezolinetant Table 2. Major Company of Elinzanetant Table 3. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units) Table 5. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Volume by Type (2021-2026) Table 6. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (US$ Million) Table 7. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Value by Type (2021-2026) Table 8. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Type (2021-2026) & (US$/Unit) Table 9. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2027-2032) & (K Units) Table 10. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Volume by Type (2027-2032) Table 11. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2027-2032) & (US$ Million) Table 12. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Value by Type (2027-2032) Table 13. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Type (2027-2032) & (US$/Unit) Table 14. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units) Table 15. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units) Table 17. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units) Table 21. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2021-2026) & (US$ Million) Table 24. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Trends Table 25. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Drivers Table 26. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Opportunities and Challenges Table 27. Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Restraints Table 28. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Company (2021-2026) Table 30. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Company (2021-2026) & (K Units) Table 31. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Company (2021-2026) Table 32. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Major Company Production Sites and Headquarters Table 35. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Company, Product Type & Application Table 36. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2021-2026) & (K Units) Table 41. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Volume by Region (2021-2026) Table 42. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2021-2026) & (US$ Million) Table 43. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Value by Region (2021-2026) Table 44. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2027-2032) & (K Units) Table 46. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Volume by Region (2027-2032) Table 47. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2027-2032) & (US$ Million) Table 48. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Value by Region (2027-2032) Table 49. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units) Table 52. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Volume by Application (2021-2026) Table 53. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (US$ Million) Table 54. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Value by Application (2021-2026) Table 55. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Application (2021-2026) & (US$/Unit) Table 56. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2027-2032) & (K Units) Table 57. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Volume by Application (2027-2032) Table 58. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2027-2032) & (US$ Million) Table 59. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Value by Application (2027-2032) Table 60. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Price by Application (2027-2032) & (US$/Unit) Table 61. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units) Table 62. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units) Table 64. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units) Table 68. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2021-2026) & (US$ Million) Table 71. Astellas Pharma Company Information Table 72. Astellas Pharma Business Overview Table 73. Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio Table 75. Astellas Pharma Recent Development Table 76. Bayer Company Information Table 77. Bayer Business Overview Table 78. Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio Table 80. Bayer Recent Development Table 81. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 82. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 83. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2021-2026) Table 84. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecast by Country (2027-2032) & (K Units) Table 85. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share Forecast by Country (2027-2032) Table 86. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 87. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country (2021-2026) & (US$ Million) Table 88. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Share by Country (2021-2026) Table 89. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Forecast by Country (2027-2032) & (US$ Million) Table 90. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Share Forecast by Country (2027-2032) Table 91. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 92. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 93. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2021-2026) Table 94. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecast by Country (2027-2032) & (K Units) Table 95. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share Forecast by Country (2027-2032) Table 96. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 97. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country (2021-2026) & (US$ Million) Table 98. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Share by Country (2021-2026) Table 99. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Forecast by Country (2027-2032) & (US$ Million) Table 100. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Share Forecast by Country (2027-2032) Table 101. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 102. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 103. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2021-2026) Table 104. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecast by Country (2027-2032) & (K Units) Table 105. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share Forecast by Country (2027-2032) Table 106. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 107. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country (2021-2026) & (US$ Million) Table 108. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Share by Country (2021-2026) Table 109. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Forecast by Country (2027-2032) & (US$ Million) Table 110. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Share Forecast by Country (2027-2032) Table 111. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 112. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 113. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2021-2026) Table 114. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecast by Country (2027-2032) & (K Units) Table 115. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share Forecast by Country (2027-2032) Table 116. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 117. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country (2021-2026) & (US$ Million) Table 118. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Share by Country (2021-2026) Table 119. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Forecast by Country (2027-2032) & (US$ Million) Table 120. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Share Forecast by Country (2027-2032) Table 121. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 122. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026) & (K Units) Table 123. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Country (2021-2026) Table 124. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecast by Country (2027-2032) & (K Units) Table 125. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share Forecast by Country (2027-2032) Table 126. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country (2021-2026) & (US$ Million) Table 128. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Share by Country (2021-2026) Table 129. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Share Forecast by Country (2027-2032) Table 131. Key Raw Materials Table 132. Raw Materials Key Suppliers Table 133. Neurokinin Receptor Antagonists for Vasomotor Symptoms Distributors List Table 134. Neurokinin Receptor Antagonists for Vasomotor Symptoms Customers List Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Neurokinin Receptor Antagonists for Vasomotor Symptoms Image Figure 2. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size (2021-2032) & (US$ Million) Figure 4. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (2021-2032) & (K Units) Figure 5. Fezolinetant Image Figure 6. Global Fezolinetant Sales YoY Growth (2021-2032) & (K Units) Figure 7. Elinzanetant Image Figure 8. Global Elinzanetant Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Share by Type 2025 VS 2032 Figure 11. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Volume by Type in 2025 Figure 12. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Value by Type in 2025 Figure 13. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Volume by Type in 2025 Figure 14. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Value by Type in 2025 Figure 17. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Neurokinin Receptor Antagonists for Vasomotor Symptoms Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital and Clinic Image Figure 24. Global Hospital and Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 25. Pharmacy Image Figure 26. Global Pharmacy Sales YoY Growth (2021-2032) & (K Units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Share by Application 2025 VS 2032 Figure 31. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Volume by Application in 2025 Figure 32. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Value by Application in 2025 Figure 33. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Volume by Application in 2025 Figure 34. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Value by Application in 2025 Figure 37. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share in Value by Application in 2025 Figure 41. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Neurokinin Receptor Antagonists for Vasomotor Symptoms Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Neurokinin Receptor Antagonists for Vasomotor Symptoms Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Fezolinetant
  • Elinzanetant
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Astellas Pharma
  • Bayer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Type
  6. 1.3.1 Fezolinetant
  7. 1.3.2 Elinzanetant
  8. 1.4 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Type
  9. 1.4.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Trends
  2. 2.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Drivers
  3. 2.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Opportunities and Challenges
  4. 2.4 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2021-2026)
  2. 3.2 Global Top Players by Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (2021-2026)
  3. 3.3 Global Top Players by Neurokinin Receptor Antagonists for Vasomotor Symptoms Price (2021-2026)
  4. 3.4 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Major Company Production Sites & Headquarters
  6. 3.6 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Company, Product Type & Application
  7. 3.7 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neurokinin Receptor Antagonists for Vasomotor Symptoms Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neurokinin Receptor Antagonists for Vasomotor Symptoms Tier 1, Tier 2, and Tier 3
4 Neurokinin Receptor Antagonists for Vasomotor Symptoms Regional Status and Outlook
  1. 4.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Historic Market Size by Region
  3. 4.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Forecasted Market Size by Region
  7. 4.3.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Neurokinin Receptor Antagonists for Vasomotor Symptoms by Application
  1. 5.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Application
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Application
  6. 5.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Astellas Pharma
  2. 6.1.1 Astellas Pharma Company Information
  3. 6.1.2 Astellas Pharma Business Overview
  4. 6.1.3 Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio
  6. 6.1.5 Astellas Pharma Recent Developments
  7. 6.2 Bayer
  8. 6.2.1 Bayer Company Information
  9. 6.2.2 Bayer Business Overview
  10. 6.2.3 Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio
  12. 6.2.5 Bayer Recent Developments
7 North America by Country
  1. 7.1 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country
  2. 7.1.1 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026)
  4. 7.1.3 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecast by Country (2027-2032)
  5. 7.2 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country
  6. 7.2.1 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country (2021-2026)
  8. 7.2.3 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country
  2. 8.1.1 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026)
  4. 8.1.3 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country
  6. 8.2.1 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country (2021-2026)
  8. 8.2.3 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country
  2. 9.1.1 Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country
  6. 9.2.1 Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country
  2. 10.1.1 South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026)
  4. 10.1.3 South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecast by Country (2027-2032)
  5. 10.2 South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country
  6. 10.2.1 South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country (2021-2026)
  8. 10.2.3 South America Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country
  2. 11.1.1 Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country
  6. 11.2.1 Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Value Chain Analysis
  2. 12.1.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Neurokinin Receptor Antagonists for Vasomotor Symptoms Production Mode & Process
  7. 12.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Distributors
  10. 12.2.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst